1. Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics.
- Author
-
Rexach JE, Cheng Y, Chen L, Polioudakis D, Lin LC, Mitri V, Elkins A, Han X, Yamakawa M, Yin A, Calini D, Kawaguchi R, Ou J, Huang J, Williams C, Robinson J, Gaus SE, Spina S, Lee EB, Grinberg LT, Vinters H, Trojanowski JQ, Seeley WW, Malhotra D, and Geschwind DH
- Subjects
- Humans, Aged, Male, Female, Brain metabolism, Brain pathology, Dementia genetics, Dementia pathology, Dementia metabolism, Neuroglia metabolism, Neuroglia pathology, Aged, 80 and over, Middle Aged, RNA-Seq, Single-Cell Analysis, Alzheimer Disease genetics, Alzheimer Disease pathology, Alzheimer Disease metabolism, Frontotemporal Dementia genetics, Frontotemporal Dementia pathology, Frontotemporal Dementia metabolism, Supranuclear Palsy, Progressive genetics, Supranuclear Palsy, Progressive metabolism, Supranuclear Palsy, Progressive pathology, Genomics methods, Neurons metabolism, Neurons pathology, Gene Regulatory Networks
- Abstract
The development of successful therapeutics for dementias requires an understanding of their shared and distinct molecular features in the human brain. We performed single-nuclear RNA-seq and ATAC-seq in Alzheimer's disease (AD), frontotemporal dementia (FTD), and progressive supranuclear palsy (PSP), analyzing 41 participants and ∼1 million cells (RNA + ATAC) from three brain regions varying in vulnerability and pathological burden. We identify 32 shared, disease-associated cell types and 14 that are disease specific. Disease-specific cell states represent glial-immune mechanisms and selective neuronal vulnerability impacting layer 5 intratelencephalic neurons in AD, layer 2/3 intratelencephalic neurons in FTD, and layer 5/6 near-projection neurons in PSP. We identify disease-associated gene regulatory networks and cells impacted by causal genetic risk, which differ by disorder. These data illustrate the heterogeneous spectrum of glial and neuronal compositional and gene expression alterations in different dementias and identify therapeutic targets by revealing shared and disease-specific cell states., Competing Interests: Declaration of interests D.H.G. has received research funding from Hoffman-LaRoche for this project. D.C. is a full-time employee of F. Hoffmann-La Roche, Basel, Switzerland. During the study period, D.M. was a full-time employee of F. Hoffmann-La Roche, Basel, Switzerland, and is currently a full-time employee of Biogen, Cambridge, MA, USA., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF